KIT A502_Y503insAY

CI-VAR-00000105Explore in graph →NP_000213.1:p.Ala502_Tyr503insAlaTyrNM_000222.3:c.1506_1507insGCCTATCIViC 1558

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm3
KIT A502_Y503insAY	Imatinib	Predictive	D	Supports Resistance	2	submitted	EID4505 In an in vitro study, Chinese hamster ovary cells expressing KIT A502_Y503INSAY demonstrated comparable resistance to imatinib treatment compared to CHO cells expressing ligand activated wild-type KIT… (full text at CIViC) PMID 18955458 · Heinrich et al., 2008 · Open in CIViC	civic
KIT A502_Y503insAY	Sunitinib	Predictive	D	Does Not Support Resistance	2	accepted	EID4100 In an in vitro study, Chinese hamster ovary cells expressing KIT A502_Y503INSAY demonstrated comparable sensitivity to sunitinib treatment compared to CHO cells expressing ligand activated wild-type K… (full text at CIViC) PMID 18955458 · Heinrich et al., 2008 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.